Cencora Announces New Organizational and Reporting Structure to Enhance Visibility and Focus

Cencora (NYSE: COR) is realigning its corporate and reporting structure, bringing its specialty businesses together under Richard Tremonte.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- Cencora, Inc. (NYSE: COR) today announced that it is realigning its corporate and reporting structure to strengthen execution and visibility.

“Over the last two years, Cencora has taken significant steps to advance our strategy through investments to further our leadership in specialty and enhance our service to our customers and partners. Our realigned organizational structure reflects our focus on ensuring Cencora is uniquely positioned as a leader in supporting pharmaceutical innovation,” said Robert P. Mauch, President and Chief Executive Officer of Cencora. “The updated reporting structure will also give our shareholders a clearer view of our progress against our strategic priorities and how we are creating sustainable, long-term value across our enterprise.”

To better support its specialty provider and manufacturer partners and capitalize on the strength of its end-to-end specialty solutions, Cencora is bringing together its specialty businesses under one leader, Richard Tremonte. These businesses will be reported under the Specialty Pharmaceutical and Provider Services segment and consist of:

• Specialty distribution and GPO services supporting access and contracting to thousands of community-based specialists across the U.S.
• Oncology and retina MSO platforms providing administrative, clinical trial and research and data and analytics services to physicians.
• Global specialty logistics supporting clinical trials and complex therapy distribution with 140 logistics sites across over 50 countries.
• Multinational third-party logistics (3PL) supporting 23 million lines across 15 countries in North America and Europe.
• Commercialization services providing hub-and-spoke solutions in Canada and global pharmacovigilance, regulatory affairs and market access solutions.

Cencora’s remaining U.S. businesses and its smaller European wholesale pharmaceutical distribution business will be organized under the Pharmaceutical Distribution and Services segment. To continue leveraging its scale and supply chain efficiency while recognizing the distinct needs of its customers, Cencora’s remaining U.S. businesses will be organized under the following verticals:

• Health Systems, led by Matthew Glucksmann: Providing comprehensive solutions to meet the needs of leading hospitals, health systems and government facilities including:
  • Integrated model for wholesale and specialty distribution
  • Holistic health system pharmacy support services, including specialty GPO services; and
  • Unit-dose repackaging
• Retail Pharmacy and Alternate Care, led by Tim Cernohous: Serving pharmacies at the heart of community health and ensuring patient access to pharmaceuticals.

Cencora’s European wholesale pharmaceutical distribution business will be led by Juan Guerra.

Cencora is providing a recast of the Company’s unaudited summary segment financial information for fiscal 2025 and 2026 in a Current Report on Form 8-K with the U.S. Securities and Exchange Commission.

About Cencora

Cencora is a global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products and solutions. Our worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #16 on the Global Fortune 500 with more than $300 billion in annual revenue.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261103773050/en/

Bennett S. Murphy
Senior Vice President, Investor Relations and Enterprise Productivity
Bennett.Murphy@cencora.com

Source: Cencora

Key Terms

gpo medical

A GPO, or group purchasing organization, is an entity that negotiates bulk-buying discounts on supplies, equipment, or services on behalf of multiple member organizations, commonly hospitals, clinics, or retailers. For investors, a GPO matters because it can lower costs for members, increase predictable revenue through membership fees or contracts, and influence supplier pricing power—similar to how a shoppers’ club secures lower prices by pooling many buyers into one large order.

third-party logistics (3pl) technical

A third-party logistics (3PL) provider is an outside company hired to handle warehousing, transportation, and distribution of goods for another business. Think of it like hiring a moving company and storage facility so a firm doesn’t manage trucks, warehouses, or deliveries itself. Investors care because using a 3PL affects costs, speed, and reliability of getting products to market, which can influence sales, margins, and operational risk.

pharmacovigilance medical

Pharmacovigilance is the process of monitoring and assessing the safety of medicines after they are on the market, ensuring that any side effects or risks are identified and managed. For investors, it matters because it helps ensure that pharmaceutical companies maintain safe products, which can influence a company’s reputation, regulatory approval, and financial stability over time.

form 8-k regulatory

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.